Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Heterogeneity in Rhabdoid Tumors : Proteomic and Single-Cell Analyses to Identify New Therapeutic Targets

ID
Name
APHP201123
Description
The investigators aim to explore the inter tumor heterogeneity by a proteomic approach of a wide series of rhabdoid tumors, from both intra and extra cranial origins.
Trial arms
Trial start
2022-08-12
Estimated PCD
2023-02-17
Trial end
2023-02-17
Status
Completed
Treatment
Mass spectrometry
Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry
Arms:
ATRT
Size
44
Primary endpoint
Identification of proteomic signature for each molecular subgroup of ATRT
3 years
Eligibility criteria
Inclusion Criteria: * Aged 0-17 years old * Rhabdoid tumor, treated in oncology departments in Ile de France * frozen samples collected in usual care * parents' agreement for samples collection in usual care Exclusion Criteria * Unconfirmed diagnosis of Rhabdoid tumor with molecular analyses Samples * paraffin embedded tissues
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 44, 'type': 'ACTUAL'}}
Updated at
2023-11-28

1 organization

1 product

1 indication

Organization
Assistance Publique - Hôpitaux de Paris
Product
Mass spectrometry
Indication
ATRT